Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma to Host Second Quarter Financial Results and Business Highlights Conference Call and Webcast on August 13, 2020
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its second quarter 2020 financial results and business highlights on Thursday, ...
View HTML
Toggle Summary RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe  COVID-19 across 40 clinical sites -- The global Phase 2/3 study has been approved in Mexico , the UK and Russia   and is also under review in Italy, Brazil and additional countries -- Enrollment in a parallel ...
View HTML
Toggle Summary RedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will participate in the following virtual conferences in August: BTIG Virtual Biotechnology ...
View HTML
Toggle Summary RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
RedHill acquired Movantik ® for opioid induced constipation from AstraZeneca in April 2020 ; Movantik ® generated $96 million in 2019 -- RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik ® with a new royalty-bearing agreement, under which RedHill will maintain ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy -- The pivotal Phase 3 study aims to enroll 125 patients at 50 clinical sites across the U.S. ...
View HTML
Toggle Summary RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy , Brazil and Mexico -- Enrollment in a parallel U.S. Phase 2 study in patients with severe COVID-19 is expected to ...
View HTML
Toggle Summary RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In ...
View HTML
Toggle Summary RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
Talicia ® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to   clarithromycin-based therapies Talicia ® is targeting an estimated two million U.S. ...
View HTML
Toggle Summary RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
Phase 2/3 study process initiated in Brazil and Mexico  The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia     Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites   Potential ...
View HTML
Toggle Summary RedHill Biopharma Seeks SEC Review of Suspicious Trading Activity
TEL-AVIV, Israel and RALEIGH, N.C. , July 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced today it is seeking regulatory review by the Securities and Exchange Commission (“SEC”), and intends to ...
View HTML